Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Curium Pharma
Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in July and August 2017.
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Group Purchasing
- Home Infusion
- Radiopharmaceuticals, Contrast Agents
- Specialty Pharmaceuticals
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- IBA Molecular
- Mallinckrodt Nuclear Medicine LLC
- MAP Medical Technologies Oy
- Zevacor Molecular